Table 1.
Population characteristics, ART status, and regimens
| All (n = 1050) | ART-Naïve (n = 467) | Art-experienced (n = 583) | |
|---|---|---|---|
| Age group (years) | |||
| 15–24 | 218 (20.8%) | 116 (24.8%) | 102 (17.5%) |
| 25–34 | 378 (36.0%) | 189 (40.5%) | 189 (32.4%) |
| 35–44 | 261(24.9%) | 99 (21.2%) | 162 (27.8%) |
| 45–54 | 147 (14.0%) | 101 (21.6%) | 46 (7.9%) |
| >55 | 74 (7.0%) | 45 (9.6%) | 29 (5.0%) |
| Sex (assigned at birth) | |||
| Female | 693 (66.0%) | 298 (63.8%) | 395 (67.8%) |
| Male | 357 (34.0%) | 169 (36.2%) | 188 (32.8%) |
| Currently on ART? | |||
| Yes | – | 603a | |
| No | – | 34 | |
| Unknown | – | 565 | |
| ART regimen | |||
| NRTI + NNRTI | 348 (89.5%) | ||
| TDF, FTC, EFV | – | 329 | |
| TDF, EFV, 3TC | – | 5 | |
| AZT, EFV, 3TC | – | 5 | |
| ABC, EFV, 3TC | – | 1 | |
| d4T, EFV, 3TC | – | 1 | |
| TDF, FTC, EFZ | – | 1 | |
| TDF, NVP, 3TC | – | 3 | |
| AZT, NVP, 3TC | – | 2 | |
| TDF, FTC, NVP | – | 1 | |
| NRTI + PI | – | 27 (6.9%) | |
| TDF, 3TC, LPV | – | 14 | |
| AZT, 3TC, LPV | – | 9 | |
| ABC, 3TC, LPV | – | 2 | |
| TDF, FTC, LPV | – | 1 | |
| TDF, ATV, LPV | – | 1 | |
| NRTI + INSTI | – | 10 (2.6%) | |
| TDF, 3TC, DTG | – | 10 | |
Data from 1202 participants with associated metadata for whom blood samples were collected and sent to the University of Oxford for sequencing. Of those, 1050 were successfully sequenced and analysed.
ABC abacavir, EFV efavirenz, FTC emtricitabine, TDF tenofovir, 3TC lamivudine, LPV/r lopinavir/ritonavir, DTG dolutegravir, d4T stavudine, NVP nevirapine, INSTI integrase strand transfer inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, PI protease inhibitors.
aParticipant is currently taking ART, but regimens were unknown in 274 participants.